NEULAND LABORATORIES LIMITED Financials Neuland Laboratories Limited NSE India S.E.
Equities
NEULANDLAB
INE794A01010
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,973 INR | -1.67% |
|
-5.36% | +31.79% |
| Apr. 12 | INDIA STOCKS-Financials drag Indian shares, hit by fading US rate cut hopes | RE |
| Mar. 31 | Neuland Laboratories Limited Announces Resignation of P.V. Maiya as Director | CI |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,652 | 3,637 | 26,788 | 13,171 | 23,087 | 89,602 | - | - |
| Enterprise Value (EV) 1 | 8,652 | 3,637 | 26,788 | 13,171 | 23,087 | 87,277 | 85,272 | 83,158 |
| P/E ratio | 51.6 x | 22.4 x | 33.2 x | 20.6 x | 14.1 x | 29 x | 28.3 x | 23.3 x |
| Yield | 0.18% | 0.71% | 0.24% | - | 0.56% | 0.17% | 0.14% | 0.21% |
| Capitalization / Revenue | 1.3 x | 0.48 x | 2.86 x | 1.38 x | 1.94 x | 5.66 x | 5.47 x | 4.6 x |
| EV / Revenue | 1.3 x | 0.48 x | 2.86 x | 1.38 x | 1.94 x | 5.52 x | 5.2 x | 4.27 x |
| EV / EBITDA | 14.8 x | 3.57 x | 18.2 x | 9.24 x | 8.49 x | 18.3 x | 18.9 x | 14.4 x |
| EV / FCF | 127 x | 42.6 x | 31.9 x | -35.3 x | 13.5 x | 36.1 x | 30.8 x | 25.8 x |
| FCF Yield | 0.79% | 2.35% | 3.13% | -2.83% | 7.41% | 2.77% | 3.25% | 3.88% |
| Price to Book | - | 0.52 x | 3.42 x | 1.58 x | - | 6.94 x | 5.59 x | 4.52 x |
| Nbr of stocks (in thousands) | 12,830 | 12,830 | 12,830 | 12,830 | 12,830 | 12,830 | - | - |
| Reference price 2 | 674.4 | 283.4 | 2,088 | 1,027 | 1,799 | 6,984 | 6,984 | 6,984 |
| Announcement Date | 5/16/19 | 5/22/20 | 5/11/21 | 5/10/22 | 5/11/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6,668 | 7,627 | 9,369 | 9,511 | 11,912 | 15,825 | 16,387 | 19,484 |
| EBITDA 1 | 583.7 | 1,019 | 1,468 | 1,426 | 2,718 | 4,763 | 4,503 | 5,786 |
| EBIT 1 | - | 706.1 | 1,071 | 935.8 | - | 4,373 | 4,064 | 5,318 |
| Operating Margin | - | 9.26% | 11.44% | 9.84% | - | 27.63% | 24.8% | 27.3% |
| Earnings before Tax (EBT) 1 | 203.4 | 529.2 | 1,053 | 821.6 | 2,157 | 4,144 | 4,251 | 5,164 |
| Net income 1 | 164.4 | 162.1 | 806.3 | 638.2 | 1,635 | 3,108 | 3,188 | 3,873 |
| Net margin | 2.47% | 2.13% | 8.61% | 6.71% | 13.73% | 19.64% | 19.45% | 19.88% |
| EPS 2 | 13.06 | 12.63 | 62.85 | 49.74 | 127.4 | 240.9 | 247.1 | 300.2 |
| Free Cash Flow 1 | 67.95 | 85.44 | 839.6 | -373 | 1,711 | 2,418 | 2,772 | 3,225 |
| FCF margin | 1.02% | 1.12% | 8.96% | -3.92% | 14.36% | 15.28% | 16.92% | 16.55% |
| FCF Conversion (EBITDA) | 11.64% | 8.39% | 57.19% | - | 62.93% | 50.77% | 61.56% | 55.74% |
| FCF Conversion (Net income) | 41.33% | 52.71% | 104.13% | - | 104.63% | 77.8% | 86.95% | 83.27% |
| Dividend per Share 2 | 1.200 | 2.000 | 5.000 | - | 10.00 | 12.18 | 9.890 | 14.51 |
| Announcement Date | 5/16/19 | 5/22/20 | 5/11/21 | 5/10/22 | 5/11/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,454 | 2,447 | 2,009 | 2,559 | 2,212 | 2,937 | 4,071 | 3,630 | 3,466 | 3,635 | 4,068 | 3,823 |
| EBITDA 1 | 466 | 255.1 | 256.9 | 388.7 | 286 | 693 | 1,199 | 969.2 | 884 | 1,040 | 1,175 | - |
| EBIT | - | - | - | - | - | - | - | - | - | - | 1,026 | 850.6 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | 25.22% | 22.25% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | 267.4 | 172.9 | 87.34 | 217.8 | 99.66 | 384.6 | 845.4 | 618.8 | 548 | 658 | 744 | - |
| Net margin | 10.89% | 7.07% | 4.35% | 8.51% | 4.51% | 13.09% | 20.77% | 17.05% | 15.81% | 18.1% | 18.29% | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/2/21 | 5/11/21 | 8/3/21 | 5/10/22 | 8/3/22 | 11/10/22 | 5/11/23 | 8/3/23 | - | - | - | - |
1INR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | - | - | 2,325 | 4,330 | 6,444 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 68 | 85.4 | 840 | -373 | 1,711 | 2,418 | 2,772 | 3,225 |
| ROE (net income / shareholders' equity) | 2.62% | 2.3% | 10.8% | 7.85% | 17.8% | 27.1% | 21.9% | 21.5% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 550.0 | 610.0 | 652.0 | - | 1,007 | 1,249 | 1,544 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 631 | 488 | 1,054 | 959 | 661 | 899 | 800 | 800 |
| Capex / Sales | 9.46% | 6.4% | 11.25% | 10.08% | 5.55% | 5.68% | 4.88% | 4.11% |
| Announcement Date | 5/16/19 | 5/22/20 | 5/11/21 | 5/10/22 | 5/11/23 | - | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6,984
INR
Average target price
8,300
INR
Spread / Average Target
+18.85%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- NEULANDLAB Stock
- NEULANDLAB Stock
- Financials Neuland Laboratories Limited
